About Windtree Therapeutics (OTCMKTS:WINT)
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:WINT
CUSIP25466840
Phone215-488-9300
Debt
Debt-to-Equity Ratio-0.63%
Current Ratio0.19%
Quick Ratio0.19%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.48 million
Price / Sales8.28
Cash FlowN/A
Price / CashN/A
Book Value($7.57) per share
Price / Book-0.43
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-18,440,000.00
Net Margins-1,227.48%
Return on EquityN/A
Return on Assets-289.28%
Miscellaneous
Employees29
Outstanding Shares3,770,000
Windtree Therapeutics (OTCMKTS:WINT) Frequently Asked Questions
What is Windtree Therapeutics' stock symbol?
Windtree Therapeutics trades on the OTCMKTS under the ticker symbol "WINT."
How were Windtree Therapeutics' earnings last quarter?
Windtree Therapeutics Inc (OTCMKTS:WINT) issued its earnings results on Monday, August, 21st. The biotechnology company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.23. The biotechnology company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.40 million. View Windtree Therapeutics' Earnings History.
Who are some of Windtree Therapeutics' key competitors?
Some companies that are related to Windtree Therapeutics include Champions Oncology (CSBR), BiondVax Pharmaceuticals (BVXV), Vaxart (VXRT), Proteon Therapeutics (PRTO), Microbot Medical (MBOT), Vical (VICL), Neuralstem (CUR), Oncobiologics (ONS), Genetic Technologies (GENE), Titan Pharmaceuticals (TTNP), TrovaGene (TROV), Enzon Pharmaceuticals (ENZN), Mymetics (MYMX), OXiGENE (MATN) and Gene Biotherapeutics (CRXM).
Who are Windtree Therapeutics' key executives?
Windtree Therapeutics' management team includes the folowing people:
- John R. Leone, Independent Chairman of the Board (Age 68)
- Craig Fraser, President, Chief Executive Officer, Director (Age 51)
- John A. Tattory, Chief Financial Officer, Senior Vice President (Age 49)
- Mary B. Templeton Esq., Senior Vice President, General Counsel and Corporate Secretary (Age 68)
- Kathryn A. Cole, Senior Vice President - Human Resources (Age 49)
- Steven G. Simonson M.D., Senior Vice President and Chief Development Officer (Age 56)
- William C. Roberts, Vice President - Investor Relations and Corporate Communications (Age 45)
- Michael L. Magee, Vice President - Technical Operations (Age 54)
- Mahady M. Joseph, Independent Director (Age 63)
- Bruce A. Peacock, Independent Director (Age 65)
Has Windtree Therapeutics been receiving favorable news coverage?
Media headlines about WINT stock have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Windtree Therapeutics earned a daily sentiment score of 0.13 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 49.30 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Windtree Therapeutics?
Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Windtree Therapeutics' stock price today?
One share of WINT stock can currently be purchased for approximately $3.25.
How big of a company is Windtree Therapeutics?
Windtree Therapeutics has a market capitalization of $11.50 million and generates $1.48 million in revenue each year. Windtree Therapeutics employs 29 workers across the globe.
How can I contact Windtree Therapeutics?
Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The biotechnology company can be reached via phone at 215-488-9300 or via email at [email protected]
MarketBeat Community Rating for Windtree Therapeutics (WINT)
MarketBeat's community ratings are surveys of what our community members think about Windtree Therapeutics and other stocks. Vote "Outperform" if you believe WINT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WINT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Windtree Therapeutics (OTCMKTS:WINT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Windtree Therapeutics in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | $8.00 |
| Price Target Upside: | N/A | N/A | N/A | 841.18% upside |
Windtree Therapeutics (OTCMKTS:WINT) Consensus Price Target History
Windtree Therapeutics (OTCMKTS:WINT) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Windtree Therapeutics (OTCMKTS:WINT) Earnings History and Estimates Chart
Windtree Therapeutics (OTCMKTS WINT) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2017 | Q3 2017 | | ($13.80) | | $0.02 million | View | N/A |  |
| 8/21/2017 | Q2 2017 | ($0.99) | ($0.76) | $0.40 million | $1.15 million | View | N/A | |
| 5/15/2017 | Q1 2017 | | ($1.37) | | $0.22 million | View | N/A | |
| 3/31/2017 | Q4 2016 | ($34.40) | ($15.40) | $0.50 million | $0.90 million | View | N/A | |
| 11/14/2016 | Q3 2016 | ($28.20) | ($20.00) | $0.11 million | $0.96 million | View | N/A | |
| 8/10/2016 | Q2 | ($1.64) | ($1.29) | $0.08 million | $0.11 million | View | N/A | |
| 5/12/2016 | Q116 | ($1.58) | ($1.70) | | $0.08 million | View | Listen | |
| 3/24/2016 | Q4 | ($0.70) | ($1.26) | $0.07 million | $0.66 million | View | Listen | |
| 11/5/2015 | Q3 2015 | ($11.20) | ($25.21) | $0.48 million | $0.07 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.13) | ($0.13) | $0.45 million | $0.08 million | View | Listen | |
| 5/7/2015 | Q1 2015 | ($28.01) | ($39.22) | $0.56 million | $0.19 million | View | N/A | |
| 3/16/2015 | Q414 | ($0.14) | ($0.12) | $0.54 million | $1.18 million | View | N/A | |
| 11/6/2014 | | ($0.15) | ($0.13) | $0.50 million | $0.53 million | View | N/A | |
| 8/5/2014 | Q2 14 | ($0.15) | ($0.12) | $0.26 million | $1.09 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.13) | ($0.14) | $2.69 million | $0.03 million | View | N/A | |
| 3/13/2014 | Q413 | ($0.16) | ($0.16) | $0.36 million | $0.0740 million | View | N/A | |
| 11/12/2013 | Q3 | ($0.20) | ($0.22) | $0.11 million | $0.06 million | View | Listen | |
| 8/8/2013 | Q2 2013 | ($0.28) | ($0.18) | $10.00 million | $0.1820 million | View | N/A | |
| 5/7/2013 | Q1 2013 | ($75.63) | ($81.23) | | $0.07 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.23) | ($0.31) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Windtree Therapeutics (OTCMKTS:WINT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Windtree Therapeutics (OTCMKTS WINT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 0.03%
Windtree Therapeutics (OTCMKTS WINT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/4/2018 | Pharmaceutical Holdings Lee's | Major Shareholder | Buy | 541,667 | $4.80 | $2,600,001.60 | | |
| 10/28/2016 | Craig Fraser | Insider | Buy | 7,500 | $2.05 | $15,375.00 | 7,500 | |
| 2/19/2013 | John R Leone | Director | Buy | 3,000 | $2.88 | $8,640.00 | | |
(Data available from 1/1/2013 forward)
Windtree Therapeutics (OTCMKTS WINT) News Headlines
| Source: |
|
Windtree Therapeutics (OTCMKTS:WINT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Windtree Therapeutics (OTCMKTS:WINT) Income Statement, Balance Sheet and Cash Flow Statement
Windtree Therapeutics (OTCMKTS WINT) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
